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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERSevere Hypercholesterolemia: Emerging Therapies 1935YEAR IN CARDIOLOGY SERIESAllan D. Sniderman, Sotirios Tsimikas, Sergio Fazio
Sniderman and colleagues describe the need for early identiﬁcation of individuals with
extreme elevations of low-density lipoprotein cholesterol (LDL-C); early treatment will
inhibit the progression of atherosclerosis and reduce cardiovascular disease events.
Management of severe hypercholesterolemia may require multiple lipid-lowering medications
and, for some, lipid apheresis. Several novel lipid-lowering therapies are reviewed, including a
microsomal triglyceride transfer protein inhibitor and an antisense oligonucleotide against
apolipoprotein B. PCSK9 inhibitors, which are currently in phase II and III trials, lower
LDL-C up to an additional 70% in the setting of maximally tolerated medical therapy and
have the potential to reduce LDL-C to <70 mg/dl in most patients.YEAR IN CARDIOLOGY SERIESThe Year in Valvular Heart Disease 1948
Shahbudin H. Rahimtoola
Dr. Rahimtoola provides a review and pertinent commentary on selected papers related to
valvular heart disease published in the previous year.VIEWPOINT VIEWPOINTHeart Failure: TNM-Like Classiﬁcation 1959
Francesco Fedele, Paolo Severino, Simone Calcagno, Massimo Mancone
Adoption of a system similar to the TNM Classiﬁcation of Malignant Tumors should
facilitate clinical research and patient care for patients with heart failure. Fedele and
colleagues propose a TNM-like classiﬁcation for heart failure, named HLM. H refers to the
heart dysfunction, ranging from impaired systolic or diastolic function without structural
injury to biventricular dysfunction; L is for lung dysfunction; M refers to the malfunction of
peripheral organs due to heart failure. HLM classiﬁcation is inspired by key elements of
TNM staging: simplicity, clinical usefulness, efﬁcacy for planning the therapeutic strategy,
and skill to identify patient prognosis.(continued on page A-31)
MAY 20, 2014 (continued)CLINICAL RESEARCHA-31INTERVENTIONAL CARDIOLOGYOxPL and OxCE in Human Atherosclerotic Lesions 1961
Amir Ravandi, Gregor Leibundgut, Ming-Yow Hung, Mitul Patel, Patrick M. Hutchins,
Robert C. Murphy, Anand Prasad, Ehtisham Mahmud, Yury I. Miller, Edward A. Dennis,
Joseph L. Witztum, Sotirios Tsimikas
Ravandi and colleagues collected biological material in distal protection devices to determine
whether oxidized lipids are released downstream from obstructive plaques following
percutaneous interventions. The presence of oxidized phospholipids (OxPL) and oxidized
cholesteryl esters (OxCE) was evaluated in 24 ﬁlters after uncomplicated interventions in
various vascular beds. Phosphatidylcholine-containing OxPL were identiﬁed in the extracted
lipid portion from all vascular beds. Several species of OxCE were also present. This study
documents the direct release of OxPL and OxCE during percutaneous interventions from
multiple arterial beds in humans. Entrance of bioactive oxidized lipids into the
microcirculation may mediate adverse clinical outcomes during therapeutic procedures.INTERVENTIONAL CARDIOLOGYAortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients at
Extreme Risk for Surgery
1972Jeffrey J. Popma, David H. Adams, Michael J. Reardon, Steven J. Yakubov, Neal S. Kleiman,
David Heimansohn, James Hermiller, Jr, G. Chad Hughes, J. Kevin Harrison, Joseph Coselli, Jose Diez,
Ali Kaﬁ, Theodore Schreiber, Thomas G. Gleason, John Conte, Maurice Buchbinder, G. Michael Deeb,
Blasé Carabello, Patrick W. Serruys, Sharla Chenoweth, Jae K. Oh, for the CoreValve United States
Clinical Investigators
The CoreValve Extreme Risk pivotal trial treated patients who were deemed to have an
extreme risk for surgical aortic valve replacement with a self-expanding transcatheter heart
valve. This prospective, multicenter, nonrandomized investigation had a composite endpoint
of all-cause mortality or major stroke at 12 months and compared the results with expected
outcomes for similar patients who were managed medically. All-cause mortality or major
stroke at 12 months occurred in 26% of patients in the treated group versus 43% of the
comparison group. In patients with prohibitively high surgical risk, transcatheter aortic valve
replacement with a self-expanding bioprosthesis appears to improve outcomes compared with
those who are managed medically.(continued on page A-32)
MAY 20, 2014 (continued) A-32CARDIOMETABOLIC RISKLipoprotein(a) in Familial Hypercholesterolemia 1982
Rodrigo Alonso, Eduardo Andres, Nelva Mata, Francisco Fuentes-Jiménez, Lina Badimón,
José López-Miranda, Teresa Padró, Ovidio Muñiz, Jose Luis Díaz-Díaz, Marta Mauri,
Jose María Ordovás, Pedro Mata, for the SAFEHEART Investigators
Alonso and colleagues sought to determine the relationship between lipoprotein(a) (Lp[a])
and cardiovascular disease (CVD) in a large cohort of patients with heterozygous familial
hypercholesterolemia (FH). Data were collected from the SAFEHEART (Spanish Familial
Hypercholesterolemia Cohort Study) long-term observational cohort study of a molecularly
well-deﬁned FH population. Patients with FH had higher Lp(a) plasma levels compared
with their unaffected relatives. There was a signiﬁcant difference in Lp(a) levels for those with
null versus defective mutations in the LDL receptor. In multivariate analysis, Lp(a) was an
independent predictor for cardiovascular disease in this population.
Editorial Comment: Raul D. Santos, p. 1990CARDIAC IMAGINGCCTA for Detecting Cardiac Allograft Vasculopathy 1992
Omar Wever-Pinzon, Jorge Romero, Iosif Kelesidis, James Wever-Pinzon, Carlos Manrique,
Deborah Budge, Stavros G. Drakos, Ileana L. Piña, Abdallah G. Kfoury, Mario J. Garcia, Josef Stehlik
Wever-Pinzon and colleagues performed a meta-analysis to evaluate the diagnostic accuracy
of coronary computed tomography angiography (CCTA) for detecting cardiac allograft
vasculopathy (CAV). Thirteen studies involving over 600 patients that compared CCTA
with conventional coronary angiography alone or with intravascular ultrasound were
compiled. Patient-based analyses for the detection of any CAV (more than luminal
irregularities) and signiﬁcant CAV (stenosis 50%) showed mean weighted sensitivities of
97% and 94% and a negative predictive value (NPV) of 97% and 99%. There was a strong
trend toward improved sensitivity (97% vs. 91%) and NPV (99% vs. 97%) with 64-slice
compared with 16-slice CCTA. CCTA using currently available technology appears to be a
reliable noninvasive imaging alternative for the detection of CAV.
Editorial Comment: Jon Kobashigawa, p. 2005(continued on page A-33)
MAY 20, 2014 (continued) A-33CARDIAC IMAGINGECG and Imaging Surrogates of LVH With Incident AF 2007
Jonathan Chrispin, Aditya Jain, Elsayed Z. Soliman, Eliseo Guallar, Alvaro Alonso,
Susan R. Heckbert, David A. Bluemke, João A. C. Lima, Saman Nazarian
Chrispin and colleagues examined the association between left ventricular hypertrophy
(LVH), deﬁned by cardiovascular magnetic resonance (CMR) or electrocardiography
(ECG), with incident atrial ﬁbrillation (AF) in the MESA (Multi-Ethnic Study of
Atherosclerosis). CMR-LVH was deﬁned as left ventricular mass 95th percentile for the
trial subjects. Ten ECG-LVH criteria were assessed. Both CMR- and ECG-derived LVH
were associated with an approximate doubling of the likelihood of incident AF. In this
multiethnic cohort, LVH, whether detected by CMR or ECG, identiﬁed subjects at
increased risk of AF.
Editorial Comment: Kristian Wachtell, Anders M. Greve, p. 2014HEART VALVE DISEASEElevated BNP Is Associated With Worse Survival in Patients With AS 2016Marie-Annick Clavel, Joseph Malouf, Hector I. Michelena, Rakesh M. Suri, Allan S. Jaffe,
Douglas W. Mahoney, Maurice Enriquez-Sarano
Clavel and colleagues measured serum B-type natriuretic peptide (BNP) in almost 2,000
subjects with at least moderate aortic stenosis (AS). The BNP ratio was calculated as
measured BNP/maximal normal BNP value speciﬁc to age and sex. Adjusting for all survival
determinants, a BNP ratio >1 independently predicted mortality. Eight-year survival was
62% with normal BNP, 44% with a BNP ratio 1 to 2, 25% with a BNP ratio 2 to 3, and 15%
with a BNP ratio 3. This strong link to survival was conﬁrmed in asymptomatic patients
with normal ejection fraction. In this large series of AS patients, elevated BNP was associated
with excess long-term mortality independently of and incrementally with baseline
characteristics.
Editorial Comment: Petar M. Seferovic, p. 2026(continued on page A-34)
MAY 20, 2014 (continued) A-34PEDIATRIC CARDIOLOGYPrevalence of ECG Anomalies in Young Individuals 2028Navin Chandra, Rachel Bastiaenen, Michael Papadakis, Vasileios F. Panoulas, Saqib Ghani,
Jennifer Duschl, David Foldes, Hariharan Raju, Rebecca Osborne, Sanjay Sharma
Chandra and colleagues investigated the prevalence of potentially abnormal
electrocardiogram (ECG) patterns in young individuals to assess the implications for a
nationwide screening program for conditions causing sudden cardiac death (SCD). ECGs
from 7,764 nonathletes ages 14 to 35 years were analyzed for Group 1 (training-related) and
Group 2 (potentially pathological) patterns presented in the 2010 European Society of
Cardiology position paper. Results were compared with 4,081 athletes. Group 1 patterns
occurred in 49% of nonathletes and 87% of athletes. Group 2 patterns occurred in 22% of
nonathletes and 33% of athletes. This study demonstrates a high prevalence of Group 2 ECG
patterns in the general population and suggests that over one-ﬁfth of young individuals would
require further cardiac investigation if an ECG-based screening program were implemented
using current recommendations.
Editorial Comment: Anne B. Curtis, Mohamad Bourji, p. 2035PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCHFractionated Electrograms in Brugada Syndrome 2037
Tamás Szél, Charles Antzelevitch
Szél and Antzelevitch used a canine coronary wedge model to study the etiology of late
potentials and fractionated activity in bipolar electrograms recorded from the epicardium of
the right ventricular (RV) outﬂow tract in patients with Brugada syndrome (BrS). Action
potential (AP) and bipolar electrograms were recorded from epicardial and endocardial sites
of coronary-perfused canine RV wedge preparations treated with either the Ito agonist
NS5806 or the Ca2+-channel blocker verapamil to pharmacologically mimic BrS genotypes.
Fractionated electrical activity was observed in RV epicardium, but not endocardium.
Primary conduction delay was not observed. These results suggest that the late potentials and
fractionated electrograms recorded from the RV in the setting of BrS are due to abnormal
repolarization rather than abnormal depolarization or structural abnormalities.
